Skip to main content

Biogen Royalty and other revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Royalty and other revenue at Biogen came to $13.8M for the quarter to 30 Sep 2026, up 42.3% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$9.0MJun 2024$9.7MSep 2024$11.0MMar 2025$19.6MJun 2025$9.7MSep 2025$13.2MDec 2025$9.7MMar 2026$10.0MJun 2026$13.8MSep 2026
Biogen Royalty and other revenue, every reported period
Period endingRoyalty and other revenueChange on a yearFiled
30 Sep 2026$13.8Mup 42.3%28 Oct 2026
30 Jun 2026$10.0Mdown 49.0%29 Jul 2026
31 Mar 2026$9.7Mdown 11.8%29 Apr 2026
31 Dec 2025$13.2M—6 Feb 2026
30 Sep 2025$9.7Munchanged30 Oct 2025
30 Jun 2025$19.6Mup 117.8%31 Jul 2025
31 Mar 2025$11.0M—1 May 2025
30 Sep 2024$9.7M—30 Oct 2024
30 Jun 2024$9.0M—1 Aug 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.